Article(id=1330225857760702548, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225816673301282, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.07.004, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1654531200000, receivedDateStr=2022-06-07, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080158891, onlineDateStr=2026-11-19, pubDate=1657382400000, pubDateStr=2022-07-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080158891, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080158891, creator=13701087609, updateTime=1795080158891, updator=13701087609, issue=Issue{id=1330225816673301282, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='7', pageStart='815', pageEnd='956', issueExtLink='null', onlineDate='null', pubDate='1657382400000', pubDateStr='2022-07-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080149094, creator='13701087609', updateTime=1795084753930, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330245131388695240, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225816673301282, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330245131388695241, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225816673301282, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=831, endPage=838, ext={EN=ArticleExt(id=1330225857957834837, articleId=1330225857760702548, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Clinical research progress of epigenetic anti-cancer drug, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

As one of the branches of genetics, epigenetics can affect the occurrence and progression of tumors through DNA methylation, chromatin remodeling, histone modification, non-coding RNA regulation, genomic imprinting, gene silencing, RNA editing and other mechanisms. The research and development of new drugs targeting epigenetics has become one of the hotspots of anti-cancer drugs. This article reviews the clinical research progress of epigenetic anti-cancer drugs in different therapeutic fields, combination therapy and researches in drug resistance, to provide an evidence for the follow-up research and clinical usage of these drugs.

, authors=Na NI1, Yiyun YUAN2, Qiurong CEN2, Lizhu YI2, Jiajun LI2, Junlong WANG2, *, Bing ZHOU3, *, authorsList=Na NI, Yiyun YUAN, Qiurong CEN, Lizhu YI, Jiajun LI, Junlong WANG, Bing ZHOU, authorCompany=null, correspAuthors=Junlong WANG, Bing ZHOU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330225858201104470, articleId=1330225857760702548, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=表观遗传学抗肿瘤药物的临床研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

作为遗传学的分支学科之一,表观遗传学可以通过DNA甲基化、染色质重塑、组蛋白修饰、非编码RNA调控、基因组印记、基因沉默及RNA编辑等调控机制影响肿瘤的发生和进展,以此为靶点的新药研发成为抗肿瘤药物的研发热点之一。现通过对表观遗传学抗肿瘤药物在不同治疗领域的临床研究进展、联合治疗及其在耐药机制方面的临床研究进展作综述,旨在为后续研究以及该类药物在临床上的使用提供依据。

, authors=倪娜1, 袁宜耘2, 陈秋荣2, 伊丽竹2, 李佳君2, 王俊龙2, *, 周斌3, *, authorsList=倪娜, 袁宜耘, 陈秋荣, 伊丽竹, 李佳君, 王俊龙, 周斌, authorCompany=null, correspAuthors=王俊龙, 周斌, authorNote=

倪娜,副研究员,研究方向:创新药物的临床研究。

, correspAuthorsNote=
周斌,研究员,研究方向:社会管理药学研究。
王俊龙,副研究员,研究方向:创新药物的临床研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=GSNu5Jy8YQOdzrt8YvAFUQ==, magXml=X1d9Dk6lHzj5LpCfxpH0nw==, pdfUrl=null, pdf=i+IKzan7xEMkKHvbBvOpAg==, pdfFileSize=1652679, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=uA3aCYeIDUOTlqF/YDMaUQ==, mapNumber=null, fund=null)}, authors=[Author(id=1330225858612146273, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225858687643747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225858612146273, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225858775724132, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225858612146273, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio={"content":"

倪娜,副研究员,研究方向:创新药物的临床研究。

"}, bioImg=null, bioContent=

倪娜,副研究员,研究方向:创新药物的临床研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858398236759, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=1., ext=[AuthorCompanyExt(id=1330225858402431064, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858398236759, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225858410819673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858398236759, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330225858842832998, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225860461834344, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225858842832998, language=EN, stringName=Yiyun YUAN, firstName=Yiyun, middleName=null, lastName=YUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225860537331817, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225858842832998, language=CN, stringName=袁宜耘, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225860612829291, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225860700909677, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225860612829291, language=EN, stringName=Qiurong CEN, firstName=Qiurong, middleName=null, lastName=CEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225860768018542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225860612829291, language=CN, stringName=陈秋荣, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225860835127408, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225860910624882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225860835127408, language=EN, stringName=Lizhu YI, firstName=Lizhu, middleName=null, lastName=YI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225860973539443, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225860835127408, language=CN, stringName=伊丽竹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225861032259701, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225861107757175, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861032259701, language=EN, stringName=Jiajun LI, firstName=Jiajun, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225861174866040, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861032259701, language=CN, stringName=李佳君, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225861241974906, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225861313278076, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861241974906, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225861388775549, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861241974906, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225861447495808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=6, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225861518798978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861447495808, language=EN, stringName=Bing ZHOU, firstName=Bing, middleName=null, lastName=ZHOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225861598490755, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861447495808, language=CN, stringName=周斌, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.中国医药工业研究总院中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858532454493, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=3., ext=[AuthorCompanyExt(id=1330225858540843102, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858532454493, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1330225858549231711, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858532454493, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.中国医药工业研究总院中国医药工业信息中心,上海 200040)])])], keywords=[Keyword(id=1330225861682376836, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, language=EN, orderNo=1, keyword=epigenetics), Keyword(id=1330225861766262917, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, language=EN, orderNo=2, keyword=anti-cancer drug), Keyword(id=1330225861850148998, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, language=EN, orderNo=3, keyword=clinical research), Keyword(id=1330225861975978119, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, language=CN, orderNo=1, keyword=表观遗传学), Keyword(id=1330225862043086984, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, language=CN, orderNo=2, keyword=抗肿瘤药物), Keyword(id=1330225862122778761, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, language=CN, orderNo=3, keyword=临床研究)], refs=[Reference(id=1330225862248607882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Riggs D, Porter TN. Overview of epigenetic mechanisms. In Epigenetic mechanisms of gene regulation[M]. New York: Cold Spring Harbor Laboratory Press, 1996: 45., articleTitle=null, refAbstract=null), Reference(id=1330225862412185739, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=李灿美, 杨凌, 曾云. DNA高甲基化与肿瘤的研究进展[J]. 云南医药, 2011, 32(5): 557-560., articleTitle=null, refAbstract=null), Reference(id=1330225862533820556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=张子腾, 杜秀明, 宗英, 等. 基于非编码RNAs的抗肿瘤药物研发进展[J]. 中国新药杂志, 2014, 23(15): 1762-1768., articleTitle=null, refAbstract=null), Reference(id=1330225862596735117, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts[J]. Blood, 2015, 126(3): 291-299., articleTitle=null, refAbstract=null), Reference(id=1330225862684815502, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Cseh AM, Niemeyer CM, Yoshimi A, et al. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group[J]. Br J Haematol, 2016, 172(6): 930-936., articleTitle=null, refAbstract=null), Reference(id=1330225862747730063, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Garcia-Manero G, Stoltz ML, Ward MR, et al. A pilot pharmacokinetic study of oral azactidine[J]. Leukemia, 2008, 22(9): 1680-1684., articleTitle=null, refAbstract=null), Reference(id=1330225862814838928, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Gracia-Manero G, Gore SD. Cogle C, et al. Phase Ⅰ study of oral azacitidine in myelody splastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia[J]. J Clin Oncol, 2011, 29(18): 2521-2527., articleTitle=null, refAbstract=null), Reference(id=1330225862894530705, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=苑晓磊, 胡东博, 张国福, 等. 地西他滨治疗成人急性髓系白血病临床效果及对肿瘤相关巨噬细胞、免疫功能的影响[J]. 解放军医药杂志, 2022, 34(2): 28-31., articleTitle=null, refAbstract=null), Reference(id=1330225862961639570, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=邓黎黎, 张壮苗, 梅瑜, 等. 地西他滨联合低剂量CAG方案治疗对老年AML患者血清VEGF、TSGF、TGF-β1、免疫功能及生存预后的影响[J]. 中国老年学杂志, 2022, 42(9): 2109-2112., articleTitle=null, refAbstract=null), Reference(id=1330225863016165523, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Richardson PG, Laubach JP, Lonial S, et al. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma[J]. Expert Rev Anticancer Ther, 2015, 15(7): 737-748., articleTitle=null, refAbstract=null), Reference(id=1330225863095857300, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Samuel S, Tariq MJ, Usman M, et al. Efficacy and safety of histone deacetylase inhibitors in multiple myeloma - a systematic review of early phase clinical trials[J]. Blood, 2018, 132(Suppl 1): 5629-5631., articleTitle=null, refAbstract=null), Reference(id=1330225863150383253, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=苗昭艺, 赵智刚. 淋巴瘤表观遗传学靶向治疗的进展[J]. 中国肿瘤临床, 2020, 47(7): 359-364., articleTitle=null, refAbstract=null), Reference(id=1330225863209103510, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=食药讯. 我国首批治疗外周T细胞淋巴瘤一类新药西达本胺片上市[J]. 首都食品与医药, 2015, 22(9): 66., articleTitle=null, refAbstract=null), Reference(id=1330225863267823767, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Lee HZ, Kwitkowski VE, Del Valle PL, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma[J]. Clin Cancer Res, 2015, 21(12): 2666-2670., articleTitle=null, refAbstract=null), Reference(id=1330225863322349722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Whittaker SJ, Demierre M, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2010, 28(29): 4485-4491., articleTitle=null, refAbstract=null), Reference(id=1330225864937156763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase Ⅱ study of romidepsin in relapsed or refractory peripheral T cell lymphoma after prior systemic therapy[J]. J Clin Oncol, 2012, 30(6): 631-636., articleTitle=null, refAbstract=null), Reference(id=1330225865012654236, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Piekarz RL, Frye R, Prince HM, et al. Phase Ⅱ trial of romidepsin in patients with peripheral T-cell lymphoma[J]. Blood, 2011, 117(22): 5827-5834., articleTitle=null, refAbstract=null), Reference(id=1330225865071374493, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Amengual JE, Lichtenstein R, Lue J, et al. A phase Ⅰ study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma[J]. Blood, 2018, 131(4): 397-407., articleTitle=null, refAbstract=null), Reference(id=1330225865125900446, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Martin P, Bartlett NL, Chavez JC, et al. Oral azacitidine (CC-486) plus R-CHOP in patients with high-risk or previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma (AFT-08)[J]. Blood, 2018, 132(Suppl 1): 2964., articleTitle=null, refAbstract=null), Reference(id=1330225865205592223, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Eisai Co., Ltd. Anticancer agent “Tazverik® tablets 200 mg”(tazemetostat hydrobromide) approved in Japan for EZH2 gene mutation-positive follicular lymphoma[EB/OL]. [2021-12-29]. https://www.eisai.com/news/2021/news202149.html., articleTitle=null, refAbstract=null), Reference(id=1330225865281089696, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Christiane Q, Foss FM, Kim YH, et al. Phase 1 trial of cobomarsen, an inhibitorof miR-155, in cutaneous T cell lymphoma[J]. Blood, 2018, 132(Suppl 1): 2903., articleTitle=null, refAbstract=null), Reference(id=1330225865348198561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Abramson JS, Blum KA, Flinn IW, et al. Bet inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 study[J]. Blood, 2015, 126(23): 1491., articleTitle=null, refAbstract=null), Reference(id=1330225865427890339, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Neureiter D, Jäger T, Ocker M, et al. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects[J]. World J Gastroenterol, 2014, 20(24): 7830-7848., articleTitle=null, refAbstract=null), Reference(id=1330225865486610596, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang M, Wang J, Guo J. Role of regenerating islet-derived protein 3A in gastrointestinal cancer[J]. Front Oncol, 2019, 9: 1449., articleTitle=null, refAbstract=null), Reference(id=1330225865557913765, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang J, Zhou H, Han Y, et al. SOCS3 methylation in synergy with Reg3A overexpression promotes cell growth in pancreatic cancer[J]. J Mol Med (Berl), 2014, 92(12): 1257-1269., articleTitle=null, refAbstract=null), Reference(id=1330225865637605542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Kaneta Y, Sato T, Hikiba Y, et al. Loss of pancreatic E-cadherin causes pancreatitis-like changes and contributes to carcinogenesis[J]. Cell Mol Gastroenterol Hepatol, 2020, 9(1): 105-119., articleTitle=null, refAbstract=null), Reference(id=1330225865713103015, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Rielland M, Cantor DJ, Graveline R, et al. Senescenceassociated SIN3B promotes inflammation and pancreatic cancer progression[J]. J Clin Invest, 2014, 124(5): 2125-2135., articleTitle=null, refAbstract=null), Reference(id=1330225865780211880, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Chan E, Arlinghausb LR, Cardin DB, et al. Phase Ⅰ trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer[J]. Radiother Oncol, 2016, 119(2): 312-318., articleTitle=null, refAbstract=null), Reference(id=1330225865843126441, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Ikeda M, Ohno I, Ueno H, et al. Phase Ⅰ study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer[J]. Invest New Drugs, 2019, 37(1): 109-117., articleTitle=null, refAbstract=null), Reference(id=1330225865906041002, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Chan E, Chiorean EG, O'Dwyer PJ, et al. Phase Ⅰ/Ⅱ study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors[J]. Cancer Chemother Pharmacol, 2018, 81(2): 355-364., articleTitle=null, refAbstract=null), Reference(id=1330225865968955563, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Epizyme Inc. Epizyme announces U. S. FDA accelerated approval of TazverikTM(tazemetostat) for the treatment of patients with epithelioid sarcoma[EB/OL]. [2021-12-29]. https://epizyme.gcs-web.com/news-releases/news-release-details/epizyme-announces-us-fda-accelerated-approval-tazveriktm., articleTitle=null, refAbstract=null), Reference(id=1330225866023481516, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Beg MS, Brenner AJ, Sachdev J, et al. Phase Ⅰ study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors[J]. Invest New Drugs, 2017, 35(2): 180-188., articleTitle=null, refAbstract=null), Reference(id=1330225866098978989, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Tan WW, Allred JB, Moreno-Aspitia A, et al. Phase Ⅰ study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients[J]. Clin Breast Cancer, 2016, 16(2): 82-86., articleTitle=null, refAbstract=null), Reference(id=1330225866161893550, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=于文静, 贾晋松, 王婧, 等. 维奈克拉联合阿扎胞苷治疗急性髓系白血病的近期疗效: 单中心数据[J]. 中华血液学杂志, 2022, 43(2): 134-140., articleTitle=null, refAbstract=null), Reference(id=1330225866237391023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=DiNardo CD, Stein EM, de Botton S, et al. Durable remissions from ivosidenib in IDH1-mutated relapsed or refractory AML[J]. N Engl J Med, 2018, 378(25): 2386-2398., articleTitle=null, refAbstract=null), Reference(id=1330225866338054320, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Sharma N, Chen DT, Zhao Q, et al. Lenalidomide and vorinostat maintenance after autologous transplantation in multiple myeloma: long-term follow-up[J]. Biol Blood and Marrow Transplant, 2020, 26(1): 44-49., articleTitle=null, refAbstract=null), Reference(id=1330225866451300529, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Voorhees PM, Gasparetto G, Moore DT, et al. Final results of a phase 1 study of vorinostat, pegylated liposomal doxorubicin, and bortezomib in relapsed or refractory multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2017, 17(7): 424-432., articleTitle=null, refAbstract=null), Reference(id=1330225866551963826, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Burke MJ, Kostadinov R, Sposto R, et al. Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a TACL pilot study[J]. Clin Cancer Res, 2020, 26(10): 2297-2307., articleTitle=null, refAbstract=null), Reference(id=1330225866669404339, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Hou T, Ma J, Hu C, et al. Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSFIA and GADD45 β promoter[J]. Int J Clin Exp Pathol, 2019, 12(11): 4002-4010., articleTitle=null, refAbstract=null), Reference(id=1330225866732318900, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=胡春生, 唐艳, 秦红霞, 等. 地西他滨逆转肺腺癌厄洛替尼耐药的作用及机制[J]. 中国药理学通报, 2021, 37(10): 1366-1372., articleTitle=null, refAbstract=null), Reference(id=1330225866807816373, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Hentze JL, Hogdall CK, Hogdall EV. Methylation and ovarian cancer: can DNA methylation be of diagnostic use?[J]. Mol Clin Oncol, 2019, 10(3): 323-330., articleTitle=null, refAbstract=null), Reference(id=1330225866870730934, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Hua T, Li Y, Li X, et al. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer[J]. Clin Epigenetics, 2019, 11(1): 153., articleTitle=null, refAbstract=null), Reference(id=1330225866946228407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang Y, Mei Q, Liu Y, et al. The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer[J]. Oncoimmunology, 2017, 6(9): e1323619., articleTitle=null, refAbstract=null), Reference(id=1330225867009142968, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Ozawa S, Miura T, Terashima J, et al. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review[J]. Cancer Drug Resist, 2021, 4(4): 946-964., articleTitle=null, refAbstract=null), Reference(id=1330225867076251833, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Shimizu S, Iida S, Ishiguro M, et al. Methylated BNIP3 gene in colorectal cancer prognosis[J]. Oncol Lett, 2010, 1(5): 865-872., articleTitle=null, refAbstract=null), Reference(id=1330225867139166395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Burton TR, Gibson SB. The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death[J]. Cell Death Differ, 2009, 16(4): 515-523., articleTitle=null, refAbstract=null), Reference(id=1330225867202080956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Lee V, Wang J, Zahurak M, et al. A phase Ⅰ trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan[J]. Clin Cancer Res, 2018, 24(24): 6160-6167., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1330225858398236759, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=1., ext=[AuthorCompanyExt(id=1330225858402431064, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858398236759, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225858410819673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858398236759, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)]), AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)]), AuthorCompany(id=1330225858532454493, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=3., ext=[AuthorCompanyExt(id=1330225858540843102, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858532454493, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1330225858549231711, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858532454493, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.中国医药工业研究总院中国医药工业信息中心,上海 200040)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.07.004, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.07.004, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.07.004, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.07.004, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1657382400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
表观遗传学抗肿瘤药物的临床研究进展
倪娜 1 , 袁宜耘 2 , 陈秋荣 2 , 伊丽竹 2 , 李佳君 2 , 王俊龙 2, * , 周斌 3, *
世界临床药物 | 医药专论 2022,43(7): 831-838
收起
收藏切换
世界临床药物 |医药专论 2022 , 43 (7) : 831 -838
表观遗传学抗肿瘤药物的临床研究进展
全屏
[Author(id=1330225858612146273, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225858687643747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225858612146273, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225858775724132, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225858612146273, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio={"content":"

倪娜,副研究员,研究方向:创新药物的临床研究。

"}, bioImg=null, bioContent=

倪娜,副研究员,研究方向:创新药物的临床研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858398236759, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=1., ext=[AuthorCompanyExt(id=1330225858402431064, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858398236759, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225858410819673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858398236759, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330225858842832998, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225860461834344, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225858842832998, language=EN, stringName=Yiyun YUAN, firstName=Yiyun, middleName=null, lastName=YUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225860537331817, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225858842832998, language=CN, stringName=袁宜耘, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225860612829291, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225860700909677, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225860612829291, language=EN, stringName=Qiurong CEN, firstName=Qiurong, middleName=null, lastName=CEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225860768018542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225860612829291, language=CN, stringName=陈秋荣, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225860835127408, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225860910624882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225860835127408, language=EN, stringName=Lizhu YI, firstName=Lizhu, middleName=null, lastName=YI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225860973539443, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225860835127408, language=CN, stringName=伊丽竹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225861032259701, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225861107757175, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861032259701, language=EN, stringName=Jiajun LI, firstName=Jiajun, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225861174866040, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861032259701, language=CN, stringName=李佳君, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225861241974906, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225861313278076, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861241974906, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225861388775549, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861241974906, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858465345626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=2., ext=[AuthorCompanyExt(id=1330225858469539931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225858477928540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858465345626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225861447495808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, orderNo=6, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225861518798978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861447495808, language=EN, stringName=Bing ZHOU, firstName=Bing, middleName=null, lastName=ZHOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225861598490755, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, authorId=1330225861447495808, language=CN, stringName=周斌, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.中国医药工业研究总院中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225858532454493, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, xref=3., ext=[AuthorCompanyExt(id=1330225858540843102, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858532454493, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1330225858549231711, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225857760702548, companyId=1330225858532454493, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.中国医药工业研究总院中国医药工业信息中心,上海 200040)])])]
倪娜1, 袁宜耘2, 陈秋荣2, 伊丽竹2, 李佳君2, 王俊龙2, *, 周斌3, *
作者信息
  • 1.中国医药工业研究总院药物临床研究中心,上海 200437
  • 2.上海瀛科隆医药开发有限公司,上海 200437
  • 3.中国医药工业研究总院中国医药工业信息中心,上海 200040
通讯作者:
周斌,研究员,研究方向:社会管理药学研究。
王俊龙,副研究员,研究方向:创新药物的临床研究。
作者简介:

倪娜,副研究员,研究方向:创新药物的临床研究。

Clinical research progress of epigenetic anti-cancer drug
Na NI1, Yiyun YUAN2, Qiurong CEN2, Lizhu YI2, Jiajun LI2, Junlong WANG2, *, Bing ZHOU3, *
Affiliations
  • 1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China
  • 3.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China
出版时间: 2022-07-10 doi: 10.13683/j.wph.2022.07.004
文章导航
收藏切换

作为遗传学的分支学科之一,表观遗传学可以通过DNA甲基化、染色质重塑、组蛋白修饰、非编码RNA调控、基因组印记、基因沉默及RNA编辑等调控机制影响肿瘤的发生和进展,以此为靶点的新药研发成为抗肿瘤药物的研发热点之一。现通过对表观遗传学抗肿瘤药物在不同治疗领域的临床研究进展、联合治疗及其在耐药机制方面的临床研究进展作综述,旨在为后续研究以及该类药物在临床上的使用提供依据。

表观遗传学  /  抗肿瘤药物  /  临床研究

As one of the branches of genetics, epigenetics can affect the occurrence and progression of tumors through DNA methylation, chromatin remodeling, histone modification, non-coding RNA regulation, genomic imprinting, gene silencing, RNA editing and other mechanisms. The research and development of new drugs targeting epigenetics has become one of the hotspots of anti-cancer drugs. This article reviews the clinical research progress of epigenetic anti-cancer drugs in different therapeutic fields, combination therapy and researches in drug resistance, to provide an evidence for the follow-up research and clinical usage of these drugs.

epigenetics  /  anti-cancer drug  /  clinical research
倪娜, 袁宜耘, 陈秋荣, 伊丽竹, 李佳君, 王俊龙, 周斌. 表观遗传学抗肿瘤药物的临床研究进展. 世界临床药物, 2022 , 43 (7) : 831 -838 . DOI: 10.13683/j.wph.2022.07.004
Na NI, Yiyun YUAN, Qiurong CEN, Lizhu YI, Jiajun LI, Junlong WANG, Bing ZHOU. Clinical research progress of epigenetic anti-cancer drug[J]. World Clinical Drug, 2022 , 43 (7) : 831 -838 . DOI: 10.13683/j.wph.2022.07.004

参考文献 引证文献
排序方式:
[1]
Riggs D, Porter TN. Overview of epigenetic mechanisms. In Epigenetic mechanisms of gene regulation[M]. New York: Cold Spring Harbor Laboratory Press, 1996: 45.
[2]
李灿美, 杨凌, 曾云. DNA高甲基化与肿瘤的研究进展[J]. 云南医药, 2011, 32(5): 557-560.
[3]
张子腾, 杜秀明, 宗英, 等. 基于非编码RNAs的抗肿瘤药物研发进展[J]. 中国新药杂志, 2014, 23(15): 1762-1768.
[4]
Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts[J]. Blood, 2015, 126(3): 291-299.
[5]
Cseh AM, Niemeyer CM, Yoshimi A, et al. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group[J]. Br J Haematol, 2016, 172(6): 930-936.
[6]
Garcia-Manero G, Stoltz ML, Ward MR, et al. A pilot pharmacokinetic study of oral azactidine[J]. Leukemia, 2008, 22(9): 1680-1684.
[7]
Gracia-Manero G, Gore SD. Cogle C, et al. Phase Ⅰ study of oral azacitidine in myelody splastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia[J]. J Clin Oncol, 2011, 29(18): 2521-2527.
[8]
苑晓磊, 胡东博, 张国福, 等. 地西他滨治疗成人急性髓系白血病临床效果及对肿瘤相关巨噬细胞、免疫功能的影响[J]. 解放军医药杂志, 2022, 34(2): 28-31.
[9]
邓黎黎, 张壮苗, 梅瑜, 等. 地西他滨联合低剂量CAG方案治疗对老年AML患者血清VEGF、TSGF、TGF-β1、免疫功能及生存预后的影响[J]. 中国老年学杂志, 2022, 42(9): 2109-2112.
[10]
Richardson PG, Laubach JP, Lonial S, et al. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma[J]. Expert Rev Anticancer Ther, 2015, 15(7): 737-748.
[11]
Samuel S, Tariq MJ, Usman M, et al. Efficacy and safety of histone deacetylase inhibitors in multiple myeloma - a systematic review of early phase clinical trials[J]. Blood, 2018, 132(Suppl 1): 5629-5631.
[12]
苗昭艺, 赵智刚. 淋巴瘤表观遗传学靶向治疗的进展[J]. 中国肿瘤临床, 2020, 47(7): 359-364.
[13]
食药讯. 我国首批治疗外周T细胞淋巴瘤一类新药西达本胺片上市[J]. 首都食品与医药, 2015, 22(9): 66.
[14]
Lee HZ, Kwitkowski VE, Del Valle PL, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma[J]. Clin Cancer Res, 2015, 21(12): 2666-2670.
[15]
Whittaker SJ, Demierre M, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2010, 28(29): 4485-4491.
[16]
Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase Ⅱ study of romidepsin in relapsed or refractory peripheral T cell lymphoma after prior systemic therapy[J]. J Clin Oncol, 2012, 30(6): 631-636.
[17]
Piekarz RL, Frye R, Prince HM, et al. Phase Ⅱ trial of romidepsin in patients with peripheral T-cell lymphoma[J]. Blood, 2011, 117(22): 5827-5834.
[18]
Amengual JE, Lichtenstein R, Lue J, et al. A phase Ⅰ study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma[J]. Blood, 2018, 131(4): 397-407.
[19]
Martin P, Bartlett NL, Chavez JC, et al. Oral azacitidine (CC-486) plus R-CHOP in patients with high-risk or previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma (AFT-08)[J]. Blood, 2018, 132(Suppl 1): 2964.
[20]
Eisai Co., Ltd. Anticancer agent “Tazverik® tablets 200 mg”(tazemetostat hydrobromide) approved in Japan for EZH2 gene mutation-positive follicular lymphoma[EB/OL]. [2021-12-29]. https://www.eisai.com/news/2021/news202149.html.
[21]
Christiane Q, Foss FM, Kim YH, et al. Phase 1 trial of cobomarsen, an inhibitorof miR-155, in cutaneous T cell lymphoma[J]. Blood, 2018, 132(Suppl 1): 2903.
[22]
Abramson JS, Blum KA, Flinn IW, et al. Bet inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 study[J]. Blood, 2015, 126(23): 1491.
[23]
Neureiter D, Jäger T, Ocker M, et al. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects[J]. World J Gastroenterol, 2014, 20(24): 7830-7848.
[24]
Zhang M, Wang J, Guo J. Role of regenerating islet-derived protein 3A in gastrointestinal cancer[J]. Front Oncol, 2019, 9: 1449.
[25]
Wang J, Zhou H, Han Y, et al. SOCS3 methylation in synergy with Reg3A overexpression promotes cell growth in pancreatic cancer[J]. J Mol Med (Berl), 2014, 92(12): 1257-1269.
[26]
Kaneta Y, Sato T, Hikiba Y, et al. Loss of pancreatic E-cadherin causes pancreatitis-like changes and contributes to carcinogenesis[J]. Cell Mol Gastroenterol Hepatol, 2020, 9(1): 105-119.
[27]
Rielland M, Cantor DJ, Graveline R, et al. Senescenceassociated SIN3B promotes inflammation and pancreatic cancer progression[J]. J Clin Invest, 2014, 124(5): 2125-2135.
[28]
Chan E, Arlinghausb LR, Cardin DB, et al. Phase Ⅰ trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer[J]. Radiother Oncol, 2016, 119(2): 312-318.
[29]
Ikeda M, Ohno I, Ueno H, et al. Phase Ⅰ study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer[J]. Invest New Drugs, 2019, 37(1): 109-117.
[30]
Chan E, Chiorean EG, O'Dwyer PJ, et al. Phase Ⅰ/Ⅱ study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors[J]. Cancer Chemother Pharmacol, 2018, 81(2): 355-364.
[31]
Epizyme Inc. Epizyme announces U. S. FDA accelerated approval of TazverikTM(tazemetostat) for the treatment of patients with epithelioid sarcoma[EB/OL]. [2021-12-29]. https://epizyme.gcs-web.com/news-releases/news-release-details/epizyme-announces-us-fda-accelerated-approval-tazveriktm.
[32]
Beg MS, Brenner AJ, Sachdev J, et al. Phase Ⅰ study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors[J]. Invest New Drugs, 2017, 35(2): 180-188.
[33]
Tan WW, Allred JB, Moreno-Aspitia A, et al. Phase Ⅰ study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients[J]. Clin Breast Cancer, 2016, 16(2): 82-86.
[34]
于文静, 贾晋松, 王婧, 等. 维奈克拉联合阿扎胞苷治疗急性髓系白血病的近期疗效: 单中心数据[J]. 中华血液学杂志, 2022, 43(2): 134-140.
[35]
DiNardo CD, Stein EM, de Botton S, et al. Durable remissions from ivosidenib in IDH1-mutated relapsed or refractory AML[J]. N Engl J Med, 2018, 378(25): 2386-2398.
[36]
Sharma N, Chen DT, Zhao Q, et al. Lenalidomide and vorinostat maintenance after autologous transplantation in multiple myeloma: long-term follow-up[J]. Biol Blood and Marrow Transplant, 2020, 26(1): 44-49.
[37]
Voorhees PM, Gasparetto G, Moore DT, et al. Final results of a phase 1 study of vorinostat, pegylated liposomal doxorubicin, and bortezomib in relapsed or refractory multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2017, 17(7): 424-432.
[38]
Burke MJ, Kostadinov R, Sposto R, et al. Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a TACL pilot study[J]. Clin Cancer Res, 2020, 26(10): 2297-2307.
[39]
Hou T, Ma J, Hu C, et al. Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSFIA and GADD45 β promoter[J]. Int J Clin Exp Pathol, 2019, 12(11): 4002-4010.
[40]
胡春生, 唐艳, 秦红霞, 等. 地西他滨逆转肺腺癌厄洛替尼耐药的作用及机制[J]. 中国药理学通报, 2021, 37(10): 1366-1372.
[41]
Hentze JL, Hogdall CK, Hogdall EV. Methylation and ovarian cancer: can DNA methylation be of diagnostic use?[J]. Mol Clin Oncol, 2019, 10(3): 323-330.
[42]
Hua T, Li Y, Li X, et al. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer[J]. Clin Epigenetics, 2019, 11(1): 153.
[43]
Zhang Y, Mei Q, Liu Y, et al. The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer[J]. Oncoimmunology, 2017, 6(9): e1323619.
[44]
Ozawa S, Miura T, Terashima J, et al. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review[J]. Cancer Drug Resist, 2021, 4(4): 946-964.
[45]
Shimizu S, Iida S, Ishiguro M, et al. Methylated BNIP3 gene in colorectal cancer prognosis[J]. Oncol Lett, 2010, 1(5): 865-872.
[46]
Burton TR, Gibson SB. The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death[J]. Cell Death Differ, 2009, 16(4): 515-523.
[47]
Lee V, Wang J, Zahurak M, et al. A phase Ⅰ trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan[J]. Clin Cancer Res, 2018, 24(24): 6160-6167.
2022年第43卷第7期
16
5
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.07.004
  • 接收时间:2022-06-07
  • 首发时间:2026-11-19
  • 出版时间:2022-07-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-06-07
基金
作者信息
    1.中国医药工业研究总院药物临床研究中心,上海 200437
    2.上海瀛科隆医药开发有限公司,上海 200437
    3.中国医药工业研究总院中国医药工业信息中心,上海 200040

通讯作者:

周斌,研究员,研究方向:社会管理药学研究。
王俊龙,副研究员,研究方向:创新药物的临床研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.07.004
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏